NTRANatera, Inc.

$29B

Q2 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$547M+32.2% YoY

Gross Profit

$347M63.5% margin

Operating Income

-$110M-20.2% margin

Net Income

-$101M-18.5% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

+8.9%

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

$12M

Stock-Based Comp.

$93M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$511M

Stockholders' Equity

$1.2B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$547M	$413M	+32.2%
Gross Profit	$347M	$243M	+42.7%
Operating Income	-$110M	-$44M	-151.4%
Net Income	-$101M	-$37M	-169.4%

Revenue Segments

Product

$544M100%

Licensing and other

$2M0%

Geographic Segments

United States

$538M98%

Europe, Middle East, India, Africa

$5M1%

Asia Pacific and Other

$2M0%

Americas, excluding U.S.

$2M0%

NTRA Q2 2025 Earnings — Natera, Inc. Revenue & Financial Results | Market Cap Arena